PL EN


Preferences help
enabled [disable] Abstract
Number of results
2017 | 71 | 14–18
Article title

The use of metformin in patients with chronic kidney disease

Content
Title variants
PL
Stosowanie metforminy w przewlekłej chorobie nerek
Languages of publication
EN PL
Abstracts
EN
Diabetes is a disease that affects about 4% of the population, and its incidence has been growing steadily. Increasingly more young people have to face this illness, and therefore more people suffer from chronic complications. The most frequent disorder of diabetics is diabetes nephropathy. This complication makes people‘s lives very difficult – not only the life of the patients but also the doctors who must strongly restrict the base of pharmaceuticals which can be used by these patients. Metformin has become a hope for people suffering from diabetes. This medicine has many advantages such as a decrease in glycaemia through many mechanisms. Simultaneously, it does not expose diabetics to hypoglycaemia. It reduces the death rate and protects patients‘ hearts. Additionally, it positively influences body weight, and it is taken orally. Currently, this medicine is also recommended in pre-diabetes states. Unfortunately, the chronic disease of the kidneys which usually occurs during diabetes does not enable the use of metformin. According to the Polish Diabetes Association, the dose of metformin should be reduced by half in the third phase of chronic kidney disease. In next phases, metformin should be thoroughly abandoned. There are opinions about the positive influence of metformin on people suffering from kidney disorders. The above article summarizes the current knowledge of using metformin and analyzes the latest research which describe its functioning. Additionally, it confronts two stances about the use of metformin in chronic kidney disease.
PL
Cukrzyca jest chorobą, która dotyka około 4% populacji, a częstość jej występowania stale rośnie. Chorują coraz młodsze osoby, stąd problem przewlekłych powikłań dotyczy coraz większej liczby osób. Najczęstszym powikłaniem osób z cukrzycą jest nefropatia cukrzycowa, która stanowi problem nie tylko chorych, lecz także lekarzy, którzy muszą w dużym stopniu ograniczyć bazę leków stosowanych u tych pacjentów. Nadzieją dla osób chorych na cukrzycę stała się metformina – lek o wielu zaletach. Obniża glikemię drogą wielu mechanizmów, jednocześnie nie narażając na epizody hipoglikemii, zmniejsza śmiertelność, działa kardioprotekcyjnie, wykazuje korzystny wpływ na masę ciała i jest stosowana doustnie. Obecnie wskazana również w stanach przedcukrzycowych. Barierą do stosowania metforminy okazała się przewlekła choroba nerek, która rozwija się w przebiegu cukrzycy. Według Polskiego Towarzystwa Diabetologicznego powinno się zredukować dawkę metforminy o połowę w III stadium przewlekłej choroby nerek, natomiast powyżej tego stadium, odstawić całkowicie. Pojawiły się również doniesienia o pozytywnym wpływie tego leku u chorych z powikłaniami nerkowymi. Artykuł podsumowuje obecny stan wiedzy na temat zastosowania metforminy, analizuje najnowsze badania, które opisują mechanizmy jej działania, a także konfrontuje dwa stanowiska odnośnie do stosowania metforminy w przewlekłej chorobie nerek.
Discipline
Year
Volume
71
Pages
14–18
Physical description
References
  • 1. International Diabetes Federation. IDF Diabetes Atlas 7th Edition. Available online: http://www.diabetesatlas.org/key-messages.html, 2015 [Dostęp: 18.05.2016].
  • 2. Global status report of noncommunicable diseases 2014. WHO Geneva, 2012, 79–95.
  • 3. WHO. Global Health Estimates: Deaths by Cause, Age, Sex and Country, 2002–2012. WHO Geneva, 2014, 11–40.
  • 4. Lopez A.D., Murray C.C. The global burden of disease, 1990–2020. Nat. Med. 1998; 4(11): 1241–1243.
  • 5. Morrish N.J., Wang S.L., Stevens L.K., Fuller J.H., Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes.Diabetologia. 2001; 44, Suppl 2: S14–S21.
  • 6. 8% Polaków cierpi na cukrzycę. http://www.mp.pl/cukrzyca/aktualno-sci/141399,8-polakow-cierpi-na-cukrzyce [Dostęp: 14.04.2016].
  • 7. Bailey CJ. Metformin: effects on micro and macrovascular complica-tions in type 2 diabetes. Cardiovasc. Drugs Ther. 2008; 22: 215–224.
  • 8. 2016 Guidelines on the management of diabetic patients. Clinical Diabetology 2016; 5: Supl. A: A1–A73.
  • 9. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Mana-gement of Chronic Kidney Disease. Kidney Inter. Suppl. 2013; 3(1): 1–150.
  • 10. WHO. Global status report of noncommunicable diseases 2011, 65–66.
  • 11. Ritz E., Keller C., Bergis K., Strojek K. Pathogenesis and course of renal disease in IDDM/NIDDM: differences and similarities. Am. J. Hypertens. 1997; 10(9 Pt2): 202S–207S.
  • 12. Hong C.Y., Chia K.S. Markers of diabetic nephropathy. J. Diabetes Complications. 1998; 12: 43–60.
  • 13. American Diabetes Association. Standards of medical care in diabetes – 2015. Diabetes Care 2015; 38, Suppl. 1: S1–S93.
  • 14. Fyhrquist F., Saijonmaa O. Renin-angiotensin system revisited. J. Intern. Med. 2008; 264: 224–236.
  • 15. Pacurari M., Kafoury R., Tchounwou P.B., Ndebele K. The Renin– –Angiotensin–Aldosterone system in vascular inflammation and remodeling. Int. J. Inflamm. 2014: 689360.
  • 16. Sato W., Sato Y. Midkine in nephrogenesis, hypertension and kidney diseases. Br. J. Pharmacol. 2014; 171: 879–887.
  • 17. Di Marco E., Gray S.P., Jandeleit-Dahm K. Diabetes alters activation and repression of pro- and anti-inflammatory signaling pathways in the vasculature. Front Endocrinol. (Lausanne) 2013; 4: 68.
  • 18. Rincón J., Correia D., Arcaya J.L. Finol E., Fernández A., Pérez M., Yaguas K., Talavera E., Chávez M., Summer R., Romero F. Role of Angio-tensin II type 1 receptor on renal NAD(P)H oxidase, oxidative stress and inflammation in nitric oxide inhibition induced-hypertension. Life Sci. 2015; 124: 81–90.
  • 19. American Geriatrics Society Expert Panel on the Care of Older Adults with Diabetes Mellitus. Moreno G., Mangione C.M., Kimbro L., Vaisberg E. Guidelines abstracted from the American Geriatrics Society Guidelines for Improving the Care of Older Adults with Diabetes Mellitus: 2013 update. J. Am. Geriatr. Soc. 2013; 61: 2020–2026.
  • 20. Mazokopakis E.E., Starakis I.K. Recommendations for diagnosis and management of metformin-induced vitamin B12 (Cbl) deficiency. Diabetes. Res. Clin. Pract. 2012; 97: 359–367.
  • 21. Alexander G.C., Sehgal N.L., Moloney R.M., Stafford R.S. National trends in treatment of type 2 diabetes mellitus, 1994–2007. Arch. Intern. Med. 2008; 168: 2088–2094.
  • 22. Turner LW., Nartey D., Stafford RS., Singh S., Alexander G.C. Ambu-latory treatment of type 2 diabetes mellitus in the United States, 1997–2012. Diabetes Care 2014; 37: 985–992.
  • 23. Musi N., Hirshman M.F., Nygren J., Svanfeldt M., Bavenholm P., Rooyackers O., Zhou G., Williamson J.M., Ljunqvist O., Efendic S., Moller D.E., Thorell A., Goodyear L.J. Metformin increases AMP – activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002; 51: 2074–2081.
  • 24. Gunton J.E., Delhanty P.J., Takahashi S., Baxter R.C. Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J. Clin. Endocrinol. Metab. 2003; 88: 1323–1332.
  • 25. Wilcock C., Bailey C.J. Reconsideration of inhibitory effect of metfor-min on intestinal glucose absorption. J. Pharm. Pharmacol. 1991; 43: 120– –121.
  • 26. Garber A.J., Duncan T.G., Goodman A.M., Mills D.J., Rohlf L.J. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am. J. Med. 1997; 103: 491–497.
  • 27. Cusi K., Defronzo RA. Metformin: A review of its metabolic effects. Diab. Rev. 1998; 6(2): 89–131.
  • 28. Salpeter S., Greyber E., Pasternak G.A., Salpeter E.E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Cochrane Database Syst. Rev. 2006; 1: CD002967.
  • 29. Gajjala P.R., Sanati M., Jankowski J. Cellular and molecular mecha-nisms of chronic kidney disease with diabetes mellitus and cardiovascular diseases as its comorbidities. Front Immunol. 2015; 6: 340.
  • 30. Kurukulasuriya R., Banerji M.A., Chaiken R., Lebovitz H. Selective decrease in visceral fat is associated with weight loss during metformin treatment in African Americans with type 2 diabetes [abstract]. Diabetes 1999; 48: A315.
  • 31. Horodnicka-Józwa A., Petriczko E., Niewiadomska M., Radziyevska M., Walczak M. Wysiłek fizyczny u dzieci z cukrzycą typu 1. Klin. Pediatr. 2009; 17: 207–210.
  • 32. Marfella R., Acampora R., Verrazzo G., Ziccardi P., De Rosa N., Giunta R., Giugliano D. Metformin improves hemodynamic and rheological respon-ses to L-arginine in NIDDM patients. Diabetes Care 1996; 19: 934–939.
  • 33. Mather K.J., Verma S., Anderson T.J. Improved endothelial function with metformin in type 2 diabetes mellitus. J. Am. Coll. Cardiol., 2001; 37: 1344–1350.
  • 34. Lebovitz H.E. Insulin resistance: definition and consequences. Exp. Clin. Endocrinol. Diabetes. 2001; 109: 135–148.
  • 35. Skałba P., Dąbkowska-Huć A. The metabolic aspects of polycystic ovarian syndrome. Endokrynol. Pol. 2005; 6: 960–963.
  • 36. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mecha-nism and implications for pathogenesis. Endocrin. Rev. 1997; 18: 774–800.
  • 37. Pasquali R., Gambineri A., Biscotti D., Vicennati V., Gagliardi L., Colitta D., Fiorini S., Cognigni G.E., Filicori M., Morselli-Labate A.M. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2000; 85: 2767–2774.
  • 38. Kujawska-Łuczak M., Pupek-Musialik D. Metformina–efektywny lek przeciwcukrzycowy. Czy potrafimy wykorzystać jej potencjał? Forum Zabu-rzeń Metabolicznych. Forum Zaburzeń Metabolicznych 2010; 1(2): 73–82.
  • 39. Holstein A., Nahrwold D., Hinze S., Egberts E.H.Contra-indications to metformin therapy are largely disregarded. Diabet. Med. 1999; 16: 692–696.
  • 40. Lalau J.D., Lemaire-Hurtel A.S., Lacroix C. Establishment of a database of metformin plasma concentrations and erythrocyte levels in normal and emergency situations. Clin. Drug. Investig. 2011; 31: 435–438.
  • 41. Frid A., Sterner G.N., Löndahl M., Wiklander C., Cato A., Vinge E., Andersson A. Novel assay of metformin levels in patients with type 2 dia-betes and varying levels of renal function: clinical recommendations. Diabetes Care 2010; 33: 1291–1293.
  • 42. Hirst J.A., Farmer A.J., Ali R., Roberts N.W., Stevens R.J. Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care 2012; 35: 446–454.
  • 43. Briet C., Saraval-Gross M., Kajbaf F., Fournier A., Hary L., Lalau J.D. Erythrocyte metformin levels in patients with type 2 diabetes and varying severity of chronic kidney disease. Clin. Kidney J. 2012; 5: 65–67.
  • 44. Duong J.K., Kumar S.S., Kirkpatrick C.M., Greenup L.C., Arora M., Lee T.C., Timmins P., Graham G.G., Furlong T.J., Greenfield J.R., Williams K.M., Day R.O. Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function. Clin. Pharmacokinet. 2013; 52: 373–384.
  • 45. Duong J.K., Roberts D.M., Furlong T.J., Kumar S.S., Greenfield R., Kirkpatrick C.M., Graham G.G., Williams K.M., Day R.O. Metformin thera-py in patients with chronic kidney disease. Diabetes Obes. Metab. 2012; 14: 963–965.
  • 46. Roussel R., Travert F., Pasquet B., Wilson P.W., Smith S.C. Jr, Goto S., Ravaud P., Marre M., Porath A., Bhatt D.L., Steg P.G. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch. Intern. Med. 2010; 170: 1892–1899.
  • 47. Cohen D. European drugs agency clashes with scientists over safety of GLP-1 drugs. BMJ 2013; 347: f4838.
  • 48. Szczeklik A. Choroby wewnętrzne: stan wiedzy na rok 2015. Medycyna Praktyczna, Kraków 2015, s. 1433–1437.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-889f3775-723b-4a15-a359-79e0a77eee2a
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.